Ph.D., Joint program of Massachusetts Institute of Technology and National University of Singapore, 2013
email@example.com | (516) 367-5414
The research in my laboratory addresses a central question in hematopoiesis—which is how self-renewal and differentiation are properly balanced in the hematopoietic stem and progenitor cell population. We utilize both CRISPR/Cas functional genomic and chemical genomic approaches to identify novel regulators of self-renewal and aim to develop novel therapeutic strategies for hematopoietic diseases and malignancies.
Stem and progenitor cells of many adult lineages undergo self-renewal. Exploiting self-renewal mechanisms holds great promise for the development of regenerative medical strategies and for the prevention of abnormal cell proliferation in cancer. Our research centers on normal and malignant stem and progenitor cells in the hematopoietic system. Thus far, we have utilized CRISPR/Cas functional genomics to uncover novel regulators of self-renewal of early erythroid progenitor, the insufficiency of which contributes to refractoriness of myelodysplastic syndrome to current therapies. Through collaborations with medicinal chemists, we have built pharmacological approaches to target these regulators, and these findings will help treat refractory myelodysplastic syndrome and a broad spectrum of anemias of cancer chemotherapy and radiation therapy. Our newfound knowledge of self-renewal in normal cells also helped us to understand the uniqueness of malignant cells. As an effort to identify mechanistic divergence between normal and malignant hematopoietic stem and progenitor cells, we seek to selectively inhibit self-renewal and its related metabolic processes in leukemic cells as novel therapeutic strategies for leukemia.
2013 Chinese Government Award for Outstanding Self-finance Students Abroad
2008 Tsinghua University Outstanding Master Degree Thesis Award